What Is Quinolinic Acid? Normal vs Optimal Range Explained

Most laboratories report quinolinic acid with an upper reference limit near 6 mmol/mol creatinine, but that cutoff only flags advanced neuroinflammation. A reading of 4.5 would pass as "normal" while your brain is already experiencing low-grade excitotoxicity from NMDA receptor overstimulation. Quinolinic acid is produced when activated immune cells (macrophages and microglia) shunt tryptophan through the kynurenine pathway instead of the serotonin pathway. The CTD (Comparative Toxicogenomics Database) maps 1,834 gene–chemical interactions for kynurenine pathway metabolites, confirming that immune activation directly regulates the enzymes (IDO1, IDO2, TDO) that control this tryptophan fork in the road. Keeping quinolinic acid below 3.5 means the immune system isn't commandeering your tryptophan supply at the expense of serotonin.

The neurotoxicity of quinolinic acid operates through a specific mechanism: it binds NMDA receptors on neurons, forcing calcium influx that generates free radicals and eventually kills the cell. This is excitotoxicity—the same process implicated in stroke, traumatic brain injury, and neurodegenerative disease. PubMed indexes over 3,400 publications on quinolinic acid neurotoxicity, with the strongest associations in major depressive disorder, Huntington's disease, and HIV-associated dementia. ChEMBL catalogs 592 bioactivity records for compounds targeting the kynurenine pathway, reflecting growing pharmaceutical interest in blocking quinolinic acid production. For the person reading this OAT result, a level between 3.5 and 6 doesn't mean everything is fine—it means your brain's serotonin supply is already being diverted toward a neurotoxic endpoint.

The clinical pattern that makes quinolinic acid so valuable is the inflammation-steals-serotonin signature. When quinolinic acid is high and 5-HIAA (serotonin's breakdown product) is simultaneously low, it confirms that chronic inflammation—not a primary neurotransmitter deficit—is driving mood symptoms. This distinction matters enormously for treatment: an SSRI won't solve the problem if the underlying issue is that inflammatory cytokines are activating IDO and shunting tryptophan before it ever reaches the serotonin pathway. Checking hs-CRP and IL-6 alongside quinolinic acid completes the picture, revealing whether systemic inflammation is the upstream driver and whether anti-inflammatory interventions should precede or accompany antidepressant therapy.

“Kynurenine pathway metabolites serve as mediators of exercise-induced mood enhancement, fatigue resistance, and neuroprotection, highlighting the therapeutic potential of modulating this pathway in neuroinflammatory conditions.”

— Tero-Vescan A, International Journal of Molecular Sciences (2025)